At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,735 enrolled
Drug / intervention
Molnupiravir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.
In Brief
A Phase 3 clinical trial evaluating Molnupiravir and Placebo for Coronavirus Disease (COVID-19). Completed, enrolled 1,735 participants across 173 sites in 23 countries.
Detailed Summary
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease (COVID-19)
CountriesArgentina, Brazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Israel, Italy, Japan, Mexico, Philippines, Poland, Russia, South Africa, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartOct 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedOct 5, 2020
Enrollment StartOct 19, 2020
Primary CompletionMay 5, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.7 years ago
Interventions
Molnupiravirdrug
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Placebodrug
Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)